Could it be as simple as SI actually said?
Did everyone listen to the webinar - I thought it was pretty clear.
Ryoncil for kids then talk to FDA about off-label for adults.
Revascor for kids via orphan / fast-track approval.
SI clearly stated MSB will market these on our own.
Royalties from Ryoncil and Revascor + selling the priority review voucher ($100 - $150 million) will go a long way to clearing any outstanding debts and put MSB in a stronger position re: funding via a JV or a CR after Ryoncil approval.
That was my take anyway.
Ann: Annual Financial Results Presentation, page-134
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |